Howard County will dispense the biannual prevention injection Yeztugo, a less time-consuming option than current preventative ...

HIV PREVENTION. BETHEL. >> YEAH, SO. >> THIS ISN’T JUST ABOUT MEDICINE. THIS IS ABOUT CONFIDENCE CONTROL AND PROTECTION. I TALKED TO A LOCAL ADVOCATE WHO’S LIVING WITH HIV AND PROUDLY OWNING HER STORY ...

This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...

"Gilead’s HIV ART combo deemed non-inferior in second Phase III trial" was originally created and published by Clinical ...

– Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo – – Yeztugo, Nearly 20 Years in the Making, ...

– New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ®) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, ...

A twice yearly injection that is highly effective in preventing HIV transmission could dramatically reduce infections and save lives — if the people who would most benefit from the drug can obtain it, ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

– Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to Partnerships in Developing Person-Centered Options for a Diverse Range of Populations – FOSTER CITY, ...